Healthcare of Ontario Pension Plan Trust Fund Raises Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 318,500 shares of the biopharmaceutical company’s stock after buying an additional 43,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.11% of Amicus Therapeutics worth $4,520,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Van ECK Associates Corp increased its stake in Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 873 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Amicus Therapeutics in the 3rd quarter valued at approximately $134,000. Calton & Associates Inc. purchased a new position in Amicus Therapeutics in the 4th quarter valued at approximately $142,000. Old Well Partners LLC purchased a new position in Amicus Therapeutics in the 4th quarter valued at approximately $180,000. Finally, O Shaughnessy Asset Management LLC increased its stake in Amicus Therapeutics by 25.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock valued at $185,000 after purchasing an additional 3,082 shares in the last quarter.

Amicus Therapeutics Price Performance

FOLD stock opened at $9.77 on Wednesday. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57. The stock’s fifty day simple moving average is $10.12 and its 200-day simple moving average is $11.78. The company has a quick ratio of 2.61, a current ratio of 3.03 and a debt-to-equity ratio of 2.97. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -19.94 and a beta of 0.74.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The business had revenue of $110.40 million for the quarter, compared to analysts’ expectations of $111.19 million. During the same quarter last year, the firm earned ($0.18) earnings per share. The business’s revenue was up 27.9% on a year-over-year basis. Equities research analysts expect that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on FOLD shares. Morgan Stanley dropped their price objective on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Friday, May 10th. UBS Group lowered their target price on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Guggenheim upgraded Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, May 14th. Wells Fargo & Company started coverage on Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, May 10th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.57.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,928,605.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.